Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy

Lehmann et al have identified four molecular subtypes of triple-negative breast cancer (TNBC)—basal-like (BL) 1, BL2, mesenchymal (M), and luminal androgen receptor—and an immunomodulatory (IM) gene expression signature modifier. Our group previously showed that the response of TNBC to neoadjuvant s...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Hiroko, Harano, Kenichi, Miura, Sakiko, Wang, Ying, Hirota, Yuko, Harada, Oi, Jolly, Mohit Kumar, Matsunaga, Yuki, Lim, Bora, Wood, Anita L., Parinyanitikul, Napa, Jin Lee, Hee, Gong, Gyungyub, George, Jason T., Levine, Herbert, Lee, Jangsoon, Wang, Xiaoping, Lucci, Anthony, Rao, Arvind, Schweitzer, Brock L., Lawrence, O. Rayne, Seitz, Robert S., Morris, Stephan W., Hout, David R., Nakamura, Seigo, Krishnamurthy, Savitri, Ueno, Naoto T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939918/
https://www.ncbi.nlm.nih.gov/pubmed/35294223
http://dx.doi.org/10.1200/PO.20.00368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939918/
https://www.ncbi.nlm.nih.gov/pubmed/35294223
http://dx.doi.org/10.1200/PO.20.00368

Ejemplares similares